Sigma receptor ligands: Applications in inflammation and oncology

Current Opinion in Investigational Drugs

Volumn 5, Issue 11, 2004, Pages 1158-1163

  Bourrie, Bernard ^a   Bribes, Estelle ^a   Derocq, Jean Marie ^a   Vidal, Hubert ^a   Casellas, Pierre ^a  

^a SANOFI   (France)

Author keywords

1; 2; Antitumor effect; Human sterol isomerase; Interleukin 10; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

1,3 BIS(2 METHYLPHENYL)GUANIDINE; 7 OXOCHOLESTANOL; [3 (4 ADAMANTAN 2 YL 3,5 DICHLOROPHENYL)ALLYL]CYCLOHEXYLETHYLAMINE; ANDRULIS; ANTIINFLAMMATORY AGENT; BINDING PROTEIN; CHLORPROMAZINE; CHOLESTANOL; CHOLESTEROL; EMOPAMIL; GAMMA INTERFERON; HALOPERIDOL; IFENPRODIL; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; ISOMERASE; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL) 2 PROPENYLAMINE; N CYCLOHEXYL N ETHYL 3 (3 CHLORO 4 CYCLOHEXYLPHENYL)PROPEN 2 YLAMINE; OPIATE RECEPTOR; PENTAZOCINE; PENTOXIFYLLINE; PROADIFEN; PROGESTERONE; PROTEIN SUBUNIT; SIGMA RECEPTOR LIGAND; SR 125329A; STEROID HORMONE; TAMOXIFEN; THALIDOMIDE; TRIFLUOPERAZINE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELLULAR DISTRIBUTION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; CROHN DISEASE; DRUG RECEPTOR BINDING; DRUG STRUCTURE; ENZYME ACTIVITY; GRAFT VERSUS HOST REACTION; HUMAN; INFLAMMATION; LIGAND BINDING; NONHUMAN; ONCOLOGY; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PSORIASIS; RHEUMATOID ARTHRITIS; SEQUENCE HOMOLOGY; SIDE EFFECT; STRUCTURE ANALYSIS;

ADAMANTANE; ANIMALS; ANTI-INFLAMMATORY AGENTS; ANTINEOPLASTIC AGENTS; CYCLOHEXANES; HUMANS; INTERLEUKIN-1; LIGANDS; RECEPTORS, SIGMA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 9144252699     PISSN: 14724472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. 3HSKF-10047 to etorphine-inaccessible sites in guinea-pig brain. Eur J Pharmacol (1981) 75(1):81-82.
2. Wolfe SA, Culp SG, De Souza EB: σ-Receptors in endocrine organs: Identification, characterization, and autoradiographic localization in rat pituitary, adrenal, testis, and ovary. Endocrinology (1989) 124(3):1160-1172.
3. Rogers C, Cecyre D, Lemaire S: Presence of sigma and phencyclidine (PCP)-like receptors in membrane preparations of bovine adrenal medulla. Biochem Pharmacol (1989) 38 15):2467-2472.
4. Wolfe SA, Kulsakdinun C, Battaglia G, Jaffe JH, De Souza EB: Initial identification and characterization of sigma receptors on human peripheral blood leukocytes. J Pharmacol Exp Ther (1988) 247(3):1114-1119.
5. 3H]-dopamine release from rat striatal slices by sigma receptor ligands. J Pharmacol Exp Ther (1994) 271(1 ):212-219.
6. Chien CC, Pasternak GW: Selective antagonism of opioid analgesia by a sigma system. J Pharmacol Exp Ther (1994) 271 3):1583-1590.
7. Bowen WD, Vilner BJ, Bandarage UK, Kuehne ME: Ibogaine and ibogamine modulate intracellular calcium levels via interaction with σ-2 receptors. Abs Soc Neurosci (1996) 22:Abs 2006.
8. + channel of class III antiarrhythmic drugs? Eur J Pharmacol (1993) 241 1):111-116.
9. Maurice T, Lockhart BP: Neuroprotective and anti-amnesic potentials of (σ) receptor ligands. Prog Neuropsychopharmacol Biol Psychiatry (1997) 21(1):69-102.
10. Casellas P, Bourrie B, Canat X, Carayon P, Buisson I, Paul R, Breliere JC, Le Fur G: Immunopharmacological profile of SR31747: In vitro and in vivo studies on humoral and cellular responses. J Neuroimmunol (1994) 52(2):193-203.
11. Carayon P, Petitpretre G, Bourne B, Le Fur G, Casellas P: In vivo effects of a new immunosuppressive a ligand SR31747, on mouse thymus. Immunopharmacol Immunotoxicol (1996) 18 2):179-191.
12. Carayon P, Bouaboula M, Loubet JF, Bourne B, Petitpretre G, Le Fur G, Casellas P: The σ ligand SR31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-γ and GM-CSF mRNA expression. Int J Immunopharmacol (1995) 17 9):753-761.
13. Vilner BJ, John CS, Bowen WD: σ-1 and σ-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res (1995) 55(2):408-413.
14. Wheeler KT, Wang LM, Wallen CA, Childers SR, Cline JM, Keng PC, Mach RH: Sigma-2 receptors as a biomarker of proliferation in solid tumours. Br J Cancer (2000) 82(6):1223-1232.
15. John CS, Vilner BJ, Geyer BC, Moody T, Bowen WD: Targeting σ receptor-binding benzamides as in vivo diagnostic and therapeutic agents for human prostate tumors. Cancer Res (1999) 59(18):4578-4583.
16. Poirot M, Garnier M, Bayard F, Riviere I, Traore M, Wilson M, Fargin A, Faye JC: The anti-proliferative properties of 4-benzylphenoxy thanamine derivatives are mediated by the anti-estrogen binding site (ABS), whereas the anti-estrogenic effects of trifluopromazine are not. Biochem Pharmacol (1990) 40 3):425-429.
17. Jones A Albright KD, Christen RD, Howell SB, McClay EF: Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites. Cancer Res (1997) 57(13):2657-2660.
18. Su TP, London ED, Jaffe JH: Steroid binding at σ receptors suggests a link between endocrine, nervous, and immune systems. Science (1988) 240(4849):219-221.
19. Moebius FF, Striessnig J, Glossmann H: The mysteries of σ receptors: New family members reveal a role in cholesterol synthesis. Trends Pharmacol Sci (1997) 18(3):67-70.
20. Bourrie B, Bribes E, De Nys N, Esclangon M, Garcia L, Galiègue S, Lair P, Paul R, Thomas C, Vernières JC, Casellas P: SSR125329A, a high affinity σ receptor ligand with potent anti-inflammatory properties. Eur J Pharmacol (2002) 456 1-3):123-131.
21. Jbilo O, Vidal H, Paul R, De Nys N, Bensaid N, Silve S, Carayon P, Davi D, Galiegue S, Bourne B, Guillemot JC et al: Purification and characterization of the human SR31747A-binding protein. A nuclear membrane protein related to yeast sterol isomerase. J Biol Chem (1997) 272(43):27107-27115.
22. Dussossoy D, Carayon P, Belugou S, Feraut D, Bord A, Goubet C, Roque C, Vidal H, Combes T, Loison G, Casellas P: Colocalization of sterol isomerase and σ(1) receptor at endoplasmic reticulum and nuclear envelope level. Eur J Biochem (1999) 263(2 ):377-386.
23. Hayashi T, Su TP: σ-1 receptors (σ1 binding sites) form raft-like microdomains and target lipid droplets on the endoplasmic reticulum: Roles in endoplasmic reticulum lipid compartmentalization and export. J Pharmacol Exp Ther (2003) 306(2):718-725.
24. 7 sterol isomerase activity in yeast. J Biol Chem (1996) 271(37):22434-22440.
25. 2+ antagonist binding protein. Molecular cloning, tissue distribution, and heterologous expression. J Biol Chem (1995) 270(13):7551-7557.
26. Vidal H, Mondesert G, Galiegue S, Carriere D, Dupuy PH, Carayon P, Combes T, Bribes E, Simony-Lafontaine J, Kramar A, Loison G, Casellas P: Identification and pharmacological characterization of SRBP-2: A novel SR31747A-binding protein. Cancer Res (2003) 63(16):4809-4818.
27. 7 isomerase activity. Biochem J (2003) 374(Pt 1):229-237.
28. Su TP, Hayashi T: Understanding the molecular mechanism of σ-1 receptors: Towards a hypothesis that σ-1 receptors are intracellular amplifiers for signal transduction. Curr Med Chem (2003) 10(20):2073-2080.
29. Langa F, Codony X, Tovar V, Lavado A, Gimenez E, Cozar P, Cantero M, Dordal A, Hernandez E, Perez P, Monroy X et al: Generation and phenotypic analysis of σ receptor type I (σ 1) knockout mice. Eur J Neurosi (2003) 18(8):2188-2196.
30. Bergeron R, de Montigny C, Debonnel G: Pregnancy reduces brain σ receptor function. Br J Pharmacol (1999) 127 8):1769-1776.
31. Derocq JM, Bourrie B, Segui M, Le Fur G, Casellas P: In vivo inhibition of endotoxin-induced pro-inflammatory cytokines production by the σ ligand SR31747. J Pharmacol Exp Ther (1995) 272(1):224-230.
32. Bourrie B, Bouaboula M, Benoit JM, Derocq JM, Esclangon M, Le Fur G, Casellas P: Enhancement of endotoxin-induced interleukin-10 production by SR31747A, a sigma ligand. Eur J Immunol (1995) 25(10):2882-2887.
33. Bourrie B, Benoit JM, Derocq JM, Esclangon M, Thomas C, Le Fur G, Casellas P: A σ ligand SR31747A potently modulates staphylococcal enterotoxin B-induced cytokine production in mice. Immunology (1996) 88(3):389-393.
34. Gannon CJ, Malone DL, Napolitano LM: Reduction of IL-10 and nitric oxide synthesis by SR31747A (σ ligand) in RAW murine macrophages. Surg Infect (2001) 2(4):267-272.
35. Su TP, Junien JL: σ receptors in the central nervous system and the periphery. In: The Sigma Receptors, Neuroscience Perspectives Series. Itzzhak Y (Ed), Academic Press, London, UK (1994):21-44.
36. 3H]-norepinephrine release evoked by N methyl-D-aspartate in the rat hippocampus. Proc Natl Acad Sci USA (1995) 92(9):3774-3778.
37. Zhu LX, Sharma S, Gardner B, Escuadro B, Atianzar K, Tashkin DP, Dubinett SM: IL-10 mediates σ 1 receptor-dependent suppression of antitumor immunity. J Immunol (2003) 170(7):3585-3591.
38. Hong W, Werling LL: Evidence that the σ1 receptor is not directly coupled to G proteins. Eur J Pharmacol (2000) 408 2):117-125.
39. Moots RJ, Al-Saffar Z, Hutchinson D, Golding SP, Young SP, Bacon PA, McLaughlin PJ: Old drug, new tricks: Haloperidol inhibits secretion of proinflammatory cytokines. Ann Rheum Dis (1999) 58(9):585-587.
40. Feldmann M, Maini RN: Anti-TNFα therapy of rheumatoid arthritis: What have we learned? Annu Rev Immunol (2001) 19 163-196.
41. Katsikis PD, Chu CQ, Brennan FM, Maini RN, Feldmann M: Immunoregulatory role of interleukin 10 in rheumatoid arthritis. J Exp Med (1994) 179(5):1517-1527.
42. Kuhn R, Lohler J, Rennick D, Rajewsky K, Muller W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75(2):263-274.
43. Finnegan A, Kaplan CD, Cao Y, Eibel H, Giant TT, Zhang J: Collagen-induced arthritis is exacerbated in IL-10-deficient mice. Arthritis Res Ther (2003) 5(1): R18-R24.
44. Cuzzocrea S, Mazzon E, Dugo L, Serraino I, Britti D, De Maio M, Caputi AP: Absence of endogeneous interleukin-10 enhances the evolution of murine type-II collagen-induced arthritis. Eur Cytokine Netw (2001) 12(4):568-580.
45. Scheinin T, Butler DM, Salway F, Scallon B, Feldmann M: Validation of the interleukin-10 knockout mouse model of colitis: Antitumor necrosis factor-antibodies suppress the progression of colitis. Clin Exp Immunol (2003) 133(1):38-43.
46. Ganesan S, Travis SPL, Ahmad T, Jazrawi R: Therapeutic inhibitors of tumor necrosis factor in Crohn's disease. Curr Opin Investig Drugs (2002) 3(9):1301-1306.
47. Van Roon JA, Bijlsma JW, Lafeber FP: Suppression of inflammation and joint destruction in rheumatoid arthritis may require a concerted action of Th2 cytokines. Curr Opin Investig Drugs (2002) 3(7):1011-1016.
48. Asadullah K, Sterry W, Stephanek K, Jasulaitis D, Leupold M, Audring H, Volk HD, Docke WD: IL-10 is a key cytokine in psoriasis. Proof of principle by IL-10 therapy: A new therapeutic approach. J Clin Invest (1998) 101(4):783-794.
49. Asadullah K, Friedrich M, Hanneken S, Rohrbach C, Audring H, Vergopoulos A, Ebeling M, Docke WD, Volk HD, Sterry W: Effects of systemic interleukin-10 therapy on psoriatic skin lesions: Histologic, immunohistologic and molecular biology findings. J Invest Dermatol (2001) 116(5):721-727.
50. Korholz D, Kunst D, Hempel L, Sohngen D, Heyll A, Bonig H, Gobel U, Zintl F, Burdach S: Decreased interleukin 10 and increased interferon-γ production in patients with chronic graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant (1997) 19(7):691-695.
51. Simony-Lafontaine J, Esslimani M, Bribes E, Gourgou S, Lequeux N, Lavail R, Grenier J, Kramar A, Casellas P: Immunocytochemical assessment of σ-1 receptor and human sterol isomerase in breast cancer and their relationship with a series of prognostic factors. Br J Cancer (2000) 82(12 ):1958-1966.
52. Vilner BJ, Bowen WD: σ-2 receptor agonists induce apoptosis in rat cerebellar granule cells and human SK-N-SH neuroblastoma cells. Abs Soc Neurosci (1997) 23:Abs 2319.
53. Kedjouar B, Daunes S, Vilner BJ, Bowen WD, Klaebe A, Faye JC, Poirot M: Structural similitudes between cytotoxic antiestrogen-binding site (AEBS) ligands and cytotoxic a receptor ligands. Evidence for a relationship between cytotoxicity and affinity for AEBS or σ-2 receptor but not for σ-1 receptor. Biochem Pharmacol (1999) 58(12):1927-1939.
54. Labit-Le Bouteiller C, Jamme MF, David M, Silve S, Lanau C, Dhers C, Picard C, Rahier A, Taton M, Loison G, Caput D et al: Antiproliferative effects of SR31747A in animal cell lines are mediated by inhibition of cholesterol biosynthesis at the sterol isomerase step. Eur J Biochem (1998) 256(2):342-349.
55. Crawford KW, Bowen WD: σ-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res (2002) 62(1):313-322.
56. Berthois Y, Bourrie B, Galiegue S, Vidal H, Carayon P, Martin PM, Casellas P: SR31747A is a a receptor ligand exhibiting antitumoural activity both in vitro and in vivo. Br J Cancer (2003) 88(3):438-446.
57. Ferrini JB, Jbilo O, Peleraux A, Combes T, Vidal H, Galiegue S, Casellas P: Transcriptomic classitication of antitumor agents: Application to the analysis of the antitumoral effect of SR31747A. Gene Expr (2003) 11(3-4):125-139.